Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
26 authors.
Sandra CodonyLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-0539-673X
Beatrice JoraLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-0030-2450
Miriam Santos-CaballeroDepartment of Pharmacology, Faculty of Medicine and Biomedical Research Center (Neurosciences Institute), University of Granada, Biosanitary Research Institute-ibs.GRANADA, Granada, Spain.ORCID 0000-0002-5713-4136
Qiongju QiuRandall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King's College London, London, UK.ORCID 0000-0001-9022-3651
Carla Calvó-TusellDepartament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, Girona, Spain.ORCID 0000-0003-2681-8460
Celia EscricheLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID 0009-0004-2968-7341
Andreea L TurcuLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0001-9732-2249
Filippo PrischiRandall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King's College London, London, UK.ORCID 0000-0003-2107-938X
Clara BartraInstitute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain.ORCID 0000-0001-7426-0751
Cristina ValInnopharma Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, Pharmacology Department, School of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.ORCID 0009-0001-8761-8545
Christophe MorisseauDepartment of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA, USA.ORCID 0000-0002-5672-6631
Belén PérezDepartment of Pharmacology, Therapeutics and Toxicology, Institute of Neurosciences, Autonomous University of Barcelona, Barcelona, Spain.
Andrea Bertran-MostazoInstitute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-7971-6540
Sílvia OsunaDepartament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, Girona, Spain.ORCID 0000-0003-3657-6469
Rubén CorpasInstitute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain.ORCID 0000-0002-7051-1493
Christian Griñán-FerréPharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona (NeuroUB), Barcelona, Spain.ORCID 0000-0002-5424-9130
Carles GaldeanoInstitute of Biomedicine of the University of Barcelona (IBUB), Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0003-1702-0369
M Isabel LozaInnopharma Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, Pharmacology Department, School of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.ORCID 0000-0003-4730-0863
Mercè PallàsPharmacology Section, Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Institute of Neuroscience, University of Barcelona (NeuroUB), Barcelona, Spain.ORCID 0000-0003-3095-4254
Coral SanfeliuInstitute of Biomedical Research of Barcelona (IIBB), CSIC, Barcelona, Spain.ORCID 0000-0002-9004-1206
Bruce D HammockDepartment of Entomology and Nematology and Comprehensive Cancer Center, University of California, Davis, CA, USA.ORCID 0000-0003-1408-8317
José BreaInnopharma Drug Screening Platform/Biofarma Research Group, CIMUS Research Center, Pharmacology Department, School of Pharmacy, University of Santiago de Compostela (USC), Santiago de Compostela, Spain.ORCID 0000-0002-5523-1979
Ferran FeixasDepartament de Química and Institut de Química Computacional i Catàlisi (IQCC), Universitat de Girona, Girona, Spain.ORCID 0000-0001-5147-0000
Maria R ConteRandall Centre for Cell and Molecular Biophysics, School of Basic and Medical Biosciences, King's College London, London, UK.ORCID 0000-0001-8558-2051
Enrique J CobosDepartment of Pharmacology, Faculty of Medicine and Biomedical Research Center (Neurosciences Institute), University of Granada, Biosanitary Research Institute-ibs.GRANADA, Granada, Spain.ORCID 0000-0003-1308-6264
Santiago VázquezLaboratori de Química Farmacèutica, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.ORCID 0000-0002-9296-6026
Funding
Workshop on Environmental Technology Transfer and EntrepreneurshipP42ES004699 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI YOUNG, THOMAS MICHAEL · 1987 to 2021
$50.1M
Supplement for bioactive lipids as effectors and indicators of the deleterious effects of human healthR35ES030443 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MORISSEAU, CHRISTOPHE HP · 2019 to 2025
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: · full record | OpenQuestion